XML 37 R26.htm IDEA: XBRL DOCUMENT v3.20.2
Stockholders' Equity (Tables)
9 Months Ended
Sep. 30, 2020
Stockholders' Equity Note [Abstract]  
Schedule of Stock-Based Compensation Expense
Stock-based compensation expense related to Cardiff Oncology equity awards have been recognized in operating results as follows:
 
Three Months Ended September 30,Nine Months Ended September 30,
2020201920202019
Included in research and development expense$104,259 $104,153 $251,212 $300,291 
Included in selling, general and administrative expense257,625 162,172 569,757 314,935 
Total stock-based compensation expense$361,884 $266,325 $820,969 $615,226 
Schedule of Assumptions to Estimate Fair Value of Stock Option Awards
The estimated fair value of stock option awards was determined on the date of grant using the Black-Scholes option valuation model with the following weighted-average assumptions during the following periods indicated:
 
Nine Months Ended September 30,
20202019
Risk-free interest rate0.44 %1.8 %
Dividend yield%%
Expected volatility of Cardiff Oncology common stock104.7 %95.5 %
Expected term5.9 years5.9 years
Summary of Stock Option Activity and of Changes in Stock Options Outstanding
A summary of stock option activity and changes in stock options outstanding is presented below:
 
Total OptionsWeighted-Average
Exercise Price
Per Share
Intrinsic
Value
Balance outstanding, December 31, 20191,015,418 $12.77 $— 
Granted969,965 $2.53  
Exercised(3,333)$2.05  
Canceled / Forfeited(46,069)$12.58  
Expired(15,275)$8.98  
Balance outstanding, September 30, 20201,920,706 $7.65 $21,766,326 
Exercisable at September 30, 2020441,434 $24.82 $4,507,516 
Schedule of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity
A summary of the RSU activity is presented below:
Total Restricted Stock UnitsWeighted-Average
Grant Date Fair Value
Per Share
Intrinsic Value
Non-vested RSUs outstanding, December 31, 201911,301 $15.38 $14,013 
Vested(10,310)$9.76 $22,875 
Non-vested RSUs outstanding, September 30, 2020991 $73.84 $14,062 
Summary of Warrant Activity and Changes in Warrants Outstanding
A summary of warrant activity and changes in warrants outstanding, including both liability and equity classifications is presented below:
 
Total WarrantsWeighted-Average
Exercise Price
Per Share
Weighted-Average
Remaining Contractual
Term
Balance outstanding, December 31, 201910,589,482 $4.08 3.7 years
Granted5,831,451 $1.70 
Exercised(9,047,582)$2.17 
Balance outstanding, September 30, 20207,373,351 $4.54 4.3 years
Schedule of Preferred Stock
A summary of our Company's classes of preferred stock is presented below:
Shares outstanding
ClassPar valueShares designatedLiquidation preferenceAs of September 30,
2020
As of December 31,
2019
Series A Convertible Preferred Stock$0.001 277,100 $606,000 60,600 60,600 
Series B Convertible Preferred Stock$0.001 8,860 None— — 
Series C Convertible Preferred Stock$0.001 200,000 None— — 
Series D Convertible Preferred Stock$0.0001 154,670 None— — 
Series E Convertible Preferred Stock$0.001 865,824 None865,824 —